Natco Pharma Limited · NSE:NATCOPHARM
Natco Pharma — Q2 FY2026 Earnings Presentation
9 slides from Natco Pharma's earnings presentation, Nov 14, 2025
Slide 1: Exchange filing cover letter: Q2 FY26 Earnings Presentation
November 14, 2025 Corporate Relationship Department Manager – Listing M/s. BSE Ltd. M/s. National Stock Exchange of India Ltd Mumbai 400 001 Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub: - Q2 FY 26 Earnings Presentation Please find enclosed herewith the Earnings Prese
Slide 2: NATCO Pharma Limited Earnings Presentation Q2FY26
NATCO Pharma Limited Earnings Presentation Q2FY26
Slide 3: Disclaimer
Disclaimer THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background information about the
Slide 4: Q2FY26 - Key Business & Consolidated Financial Highlights
Q2FY26 - Key Business & Consolidated Financial Highlights Total Revenue stood for Q2FY26 at INR 6,511atMn| INRPharma 14,630Export Mn | Pharma ExportatFormulations Formulations INR 2,858 Mnat |INR 11,470Formulations Domestic Mn | Domestic Formulations Revenue at INR Revenue at 1,054 Mn 961 Earnings B
Slide 5: Q2FY26 - Quarterly Performance
Q2FY26 - Quarterly Performance Revenue Breakup (%) – Q2FY26 Revenue Breakup (INR Mn) Q2FY26 Q2FY25 Q1FY26 3.7 7.1 3.6 API Revenue 539 496 526 7.2 Formulation 78.4 Formulation – Exports (incl profit share, license income, 11,470 12,113 11,265 Export formulation Domestic Formulation export service inc
Slide 6: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit & Loss Statement (INR Mn) Q2FY26 Q2FY25 Q1FY26 Total Revenue 14,630 14,349 13,906 Total Expenses (before finance cost and depreciation) 7,838 5,668 7,579 Earnings before interest, tax, depreciation and amortization (EBITDA) 6,792 8,681 6,327 EBITDA Margin*
Slide 7: Key Product Pipeline - USA
Key Product Pipeline - USA Para IVs in the pipeline, with 30 over 20 FTFs (incl. Sole and 13 Approved (either tentative or fully) Shared) Key Solo FTFs (Para IV) in the pipeline Key Para IV products in the pipeline (Filing on NCE-1) date Therapeutic segment/ Therapeutic segment/ Brand Molecule Brand
Slide 8: Our NCE | Cell & Gene Therapy Investments
Our NCE | Cell & Gene Therapy Investments 1 eGenesis 3 Cellogen Therapeutics Invested US$ 8 million in a biotechnology company Invested US$ 2 million focused on advanced cellular focused on xenotransplantation, by developing safe and engineering methods and gene-therapy-based effective human compati
Slide 9: Earnings Call Details – Q2FY26
Earnings Call Details – Q2FY26 The Earnings call to discuss the operational and financial performance of the company with Mr. Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer and Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences are as below: Details of the Earnings ca